TNGX biotech catalysts & pipeline

TANGO THERAPEUTICS INC · Data as of 2026-10-25

Upcoming catalysts

vopimetostat + daraxonrasib, and vopimetostat + zoldonrasib — Initial data

2026

Combination trial with vopimetostat + daraxonrasib, and vopimetostat + zoldonrasib (Revolution Medicines), phase 1/2 initial safety and efficacy data 2026

Source filing

TNG456 — Initial data

2H 2026

Release initial TNG456 data in glioblastoma and other cancers in 2H 2026

Source filing

vopimetostat — Initial data

2H 2026

Disclose vopimetostat lung cancer monotherapy data in 2H 2026

Source filing

vopimetostat — Conference presentation

Oct 23–Oct 27

Phase 1/2 data from combination study of vopimetostat + RAS(ON) inhibitors in pancreatic cancer to be presented at 2026 ESMO Congress

Source filing

vopimetostat plus daraxonrasib — Conference presentation

Oct 23–Oct 27

The results are being presented at the European Society for Medical Oncology (ESMO) 2026 Congress being held in Madrid, Spain on October 23-27, 2026.

Source filing

Explore the free biotech catalyst calendar